Navigation Links
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
Date:1/24/2010

d neutropenia; complications were rare, with only 1 patient (2 percent) having febrile neutropenia and 2 patients (4 percent) having minor bleeding issues.
  • Most other toxicities, including gastrointestinal toxicity, were similar for both regimens except for alopecia, which was more frequent with FOLPI.

  • About Picoplatin

    Picoplatin is a new and differentiated platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration.  It is designed to overcome platinum resistance associated with chemotherapy in solid tumors.  Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and can be safely administered in combination with multiple approved oncology products.  Approximately 1,100 patients have received picoplatin.  Results obtained to date suggest that hematologic events are common but manageable.  Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is commonly observed with other platinum chemotherapy drugs.  Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors.

    In addition to the Phase 2 clinical trial of picoplatin in patients with metastatic CRC, Poniard has evaluated intravenous picoplatin in the treatment of small cell lung cancer in its Phase 3 SPEAR trial.  This trial did not meet its primary endpoint of overall survival, and the Company plans to meet with the FDA to discuss a potential regulatory path forward for picoplatin in this indication.  Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with metastatic hormone-refractory prostate cancer.  Final results of the Company's Phase 1 cardiac safety trial and the Phase 1 trial of an oral formulation of picoplatin were presented in
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
    2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
    3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
    4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
    5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
    6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
    7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
    8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
    9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
    10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
    11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... , May 4, 2015   The New ... injection, Kybella, from internationally acclaimed plastic surgeon, Dr. ... and Drug Administration, is proven to reduce fat deposits ... The active ingredient in Kybella, ... gives plastic surgeons the ability to reshape this area ...
    (Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
    (Date:5/4/2015)... May 4, 2015 PAREXEL International Corporation (NASDAQ: ... the UBS Healthcare Conference on Monday, May 18, 2015, in ... and Chief Financial Officer will be making a presentation on ... A live webcast of the presentation will be available ... in the Upcoming Events portion of the main page, ...
    Breaking Medicine Technology:Dr. Rod Rohrich Provides Medical Expertise on Kybella 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 3It's Better Hearing Month 2PAREXEL International to Present at UBS Healthcare Conference 2
    ... Nov. 11 Shire plc ... biopharmaceutical company, today announced the re-launch of FOCUS ( ... patient support program for adults taking once-daily Vyvanse ... treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded ...
    ... Deloitte Recap LLC (Recap) has launched "Development ... Series by Deloitte. The series of biopharmaceutical business ... service tailored toward business development, corporate strategy, financial, ... , "Development Optimizer" provides flexible analytical tools for ...
    Cached Medicine Technology:Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 2Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 3Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 4Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 5Deloitte Recap Launches New Solution for Clinical Development 2Deloitte Recap Launches New Solution for Clinical Development 3
    (Date:5/4/2015)... York, NY (PRWEB) May 04, 2015 ... specialized insurance programs, announces the expansion of coverage for ... is a leading provider of industry-tailored insurance and proactive ... McNeil & Company, we are dedicated to providing our ... to meet their many evolving needs. We are excited ...
    (Date:5/4/2015)... Healthcare Solutions is proud to be a sponsor at ... in Baltimore, MD from May 11 – 13, 2015. ... opportunity for clients to gather to network, attend educational ... to sponsoring the event, TROY Healthcare Solutions will be ... can stop by the TROY booth and see sample ...
    (Date:5/4/2015)... 2015 Baptist Medical Center Jacksonville ... Get With The Guidelines®-Stroke Gold Plus Quality Achievement ... The award recognizes the hospital’s commitment and success ... appropriate treatment according to nationally recognized, research-based guidelines ... receive the Gold Plus Quality Achievement Award, hospitals ...
    (Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
    (Date:5/4/2015)... Los Angeles, CA (PRWEB) May 04, 2015 ... Kevin Sands, is now offering a more comfortable and ... been the restoration of choice for those who have ... patients. Dentures can feel insecure or slip at the ... the patient eats or talks. They can also painfully ...
    Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2
    ... (HealthDay News) -- A certain area of the cerebral cortex ... smoked, finds a new study. The cerebral cortex is ... in reward, impulse control and decision making. German researchers ... smokers and 21 people who never smoked. Using these images, ...
    ... work night and rotating shifts are almost twice as likely ... day shifts, according to a study by researchers at the ... current issue of the Scandinavian Journal of Work, Environment ... collected as part of Statistics Canada,s Survey of Labour and ...
    ... HealthDay Reporter , MONDAY, Nov. 1 (HealthDay News) -- There may ... exercise regularly seem to have fewer and milder colds, a new ... catch a cold two to four times a year, and children ... colds sap about $40 billion from the U.S. economy in direct ...
    ... cancer, one of the most prevalent cancers in women, ... about 40,000 deaths annually. The disease often extends to ... process in which cancer cells invade blood vessels or ... prognosis for patients. Some scientists argue that evidence ...
    ... Nov. 2 (HealthDay News) -- Extroverts are more vulnerable to ... social activity than after they,ve been alone, researchers have found. ... and 25 introverts (reserved, shy types), aged 18 to 39, ... or a "socially impoverished group." Those in the socially ...
    ... New York, NY, November 2, 2010An initiative by the ... of proven value less expensive for their employees succeeded ... to a Commonwealth Fund-supported study published in this month,s ... by Niteesh K. Choudhry at Brigham and Women,s Hospital, ...
    Cached Medicine News:Health News:Shift work linked to higher risk of work injury: UBC study 2Health News:Exercise May Help Beat the Common Cold 2Health News:Exercise May Help Beat the Common Cold 3Health News:Fox Chase researchers identify risk factors for the spread of breast cancer to lymph nodes 2Health News:Socializing Tied to Sleep Deprivation in Extroverts 2Health News:Eliminating or reducing cost-sharing for high-value prescription drugs improves medication use 2
    MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
    Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
    Single-use, non-sterile...
    Inquire...
    Medicine Products: